17 results about "PTK Inhibitors" patented technology

Disclosed is an application of a protein kinase inhibitor in preparation of a medicine for inhibiting uterine leiomyosarcoma, wherein the protein kinase inhibitor can effectively inhibit tumor growth in vitro and in vivo, and has better efficacy and safety compared with traditional chemotherapy. The protein kinase is one of the following: Wee1-like protein kinase, cyclin-dependent kinase 1, serine / threonine protein kinase 1 and serine / threonine protein kinase ATR.

Amorphous solid dispersions of the protein kinase inhibitor cabozantinib. The amorphous solid dispersions exhibit chemical and physical stability under stressed conditions. The amorphous solid dispersions may be suitable for use in pharmaceutical compositions for administration to human subjects or patients.

This specification discloses the use of alternating electric fields and DNA-dependent PK inhibitors for cancer treatment. This specification discloses the use of alternating electric fields and DNA-dependent PK inhibitors for inducing cell death. This specification discloses the use of alternating electric fields and DNA-dependent PK inhibitors to inhibit DNA repair in cancer cells having DNA strand breaks (e.g., double-strand DNA breaks). This specification discloses the use of alternating electric fields and DNA-dependent PK inhibitors to enhance the effectiveness of radiotherapy.

Amorphous solid dispersions and pharmaceutical compositions of the protein kinase inhibitor dasatinib. The pharmaceutical compositions may be used in methods of treating a proliferative disorder such as cancer, or in methods of delivering dasatinib to patients without regard to whether the patient is concurrently administered a gastric acid-reducing agent, or without regard to whether the patient has an elevated gastric pH. The compositions may be particularly suitable for patients afflicted by achlorhydria or hypochlorhydria, or Helicobacter pylori infection.

Provided is a composition comprising a polyglycolized glyceride and a compound having the following structure (I):or a pharmaceutically acceptable salt thereof. Also provided are crystalline forms of the compound of structure (I), or a pharmaceutically acceptable salt thereof. Methods of making the same, and methods for using the same in the treatment of cancer, autoimmune, inflammatory and other Pim kinase-associated diseases, disorders or conditions are also disclosed.

The present invention relates to a series of compounds for regulating activity of a protein kinase, in particular a compound for inhibiting activity of PLK1. The present invention further provides a pharmaceutical composition containing the compound, and a use of the compound and the pharmaceutical composition thereof in preparing a drug for preventing or treating diseases caused by and / or related to dysregulation of PLK1 kinase activity.

The present invention relates to a compound suitable for use as a kinase inhibitor.

The present invention is in the field of medicinal chemistry and relates to a novel pyrazolopyridine derivative and its preparation and use as therapeutic agents, in particular as TRK inhibitors. Compounds of general formula (I) and their geometric isomers or pharmaceutically acceptable salts thereof and their preparation. Preferred compounds have activity as protein kinase inhibitors, in particular tropomyosin receptor kinase (TRK) inhibitors.

The invention relates to pyrazolo-pyridine compounds which inhibit mitogen-activated protein kinase kinase 4 (MKK4) and in particular, selectively inhibit MKK4 over protein kinases JNK1 and MKK7. The compounds are useful for promoting liver regeneration or reducing or preventing hepatocyte death. They are further useful for treating osteoarthritis or rheumatoid arthritis, or CNS-related diseases.

This disclosure relates to a DNA-PK inhibitor having formula (I), (I), or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, or tautomer thereof, methods for preparing the foregoing and combinations thereof, and methods of using compounds of formula (I) in combination with DNA cleaving agents.

The present invention relates to pharmaceutical compositions comprising Akt protein kinase inhibitors with therapeutic activity against diseases such as cancer as well as processes for their preparation and their use as medicament.

The present invention belongs to the field of medicinal chemistry and relates to indazole derivatives and their use as therapeutic agents, in particular as PLK4 inhibitors. The derivatives are compounds of general formula I or general formula II, and geometric isomers, enantiomers or pharmaceutically acceptable salts thereof; preferred compounds have activity as protein kinase inhibitors, in particular as PLK4 kinase inhibitors.

Provided are methods of treating or preventing corneal endothelial disease. The present disclosure relates to corneal endothelial cell compositions comprising cultured human corneal endothelial cells and a Rho-associated, coiled-coil containing protein kinase inhibitor, and uses of the compositions for the treatment of corneal endothelial diseases, including bullous keratopathy, corneal edema, corneal leukoma, corneal endothelial inflammation, and corneal dystrophy.

This disclosure relates to a DNA-PK inhibitor having formula (I), (I), or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, or tautomer thereof, methods for preparing the foregoing and combinations thereof, and methods for using compounds of formula (I) in combination with DNA cleaving agents.

The present invention belongs to the field of medicinal chemistry, and relates to indazole derivatives and the use thereof as a therapeutic agent, in particular as a PLK4 inhibitor. The derivatives are compounds represented by general formula I or general formula II, and geometric isomers, enantiomers or pharmaceutically acceptable salts thereof. The preferred compounds have activity as protein kinase inhibitors, especially PLK4 kinase inhibitors. General formula (I). General formula (II).